Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling

Erinn S. Gideons*, Pei-Yi Lin, Melissa Mahgoub, Ege T. Kavalali, and Lisa M. Monteggia

Department of Neuroscience, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9111

Running Title: BDNF/TrkB signaling role in lithium

Words in Abstract: 153

Number of Figures: 6

To whom correspondence should be addressed.
Lisa M. Monteggia,
Department of Neuroscience,
University of Texas Southwestern Medical Center,
5323 Harry Hines Blvd., Dallas, TX 75390-9111
Tel 214-648-5548
Fax 214-648-4947
Email: lisa.monteggia@utsouthwestern.edu

*Current address:
Max Planck Institute for Experimental Medicine
Department of Molecular Neurobiology
Hermann-Rein-Str. 3
D-37075 Goettingen
Germany
Abstract

Lithium is widely used as a treatment for Bipolar Disorder although the molecular mechanisms that underlie its therapeutic effects are under debate. In this study, we show brain-derived neurotrophic factor (BDNF) is required for the antimanic-like effects of lithium but not the antidepressant-like effects in mice. We performed whole cell patch clamp recordings of hippocampal neurons to determine the impact of lithium on synaptic transmission that may underlie the behavioral effects. Lithium produced a significant decrease in α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated miniature excitatory postsynaptic current (mEPSC) amplitudes due to postsynaptic homeostatic plasticity that was dependent on BDNF and its receptor tropomyosin receptor kinase B (TrkB). The decrease in AMPAR function was due to reduced surface expression of GluA1 subunits through dynamin-dependent endocytosis. Collectively, these findings demonstrate a requirement for BDNF in the antimanic action of lithium and identify enhanced dynamin-dependent endocytosis of AMPARs as a potential mechanism underlying the therapeutic effects of lithium.
Lithium was initially reported for treatment as a mood stabilizer over 60 years ago (Cade, 1949) and is still widely used for the treatment of Bipolar Disorder (Mitchell, 2013; Poolsup et al., 2000; Vieta and Valentí, 2013). However, despite its extensive use for the treatment of bipolar disorder, the cellular and molecular mechanisms underlying its antimanic and antidepressant responses remain poorly understood (Can et al., 2014; Malhi and Outhred, 2016). Putative mechanisms for the therapeutic effects of lithium include inhibition of glycogen synthase kinase-3β (GSK3β) (Klein and Melton, 1996), upregulation of neurotrophins, as well as their receptors, and downregulation of α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) expression (Ankolekar and Sikdar, 2015; Du et al., 2004, 2010; Gray et al., 2003; Seelan et al., 2008; Wei et al., 2010) among others. However, which—if any—of these effects of lithium are the primary mechanism for treatment for bipolar disorder is currently unknown.

Earlier studies suggested a potential link between the action of lithium as a mood stabilizer and neurotrophins, in particular brain-derived neurotrophic factor (BDNF). BDNF and aberrant signaling through its high affinity receptor tropomyosin receptor kinase B (TrkB) have been proposed to underlie both the pathophysiology and treatment of bipolar disorder (Autry and Monteggia, 2012; Malhi et al., 2013; Scola and Andreazza, 2015). Previous work has shown that patients with bipolar disorder have decreased peripheral BDNF mRNA in blood lymphocytes and monocytes in comparison to healthy controls (D’Addario et al., 2012). Moreover, both manic and depressive states in patients with bipolar disorder have been associated with significantly decreased BDNF blood serum levels compared to patients in euthymic states and healthy controls (Fernandes et al., 2015; Tunca et al., 2014). Post-mortem analysis of hippocampal tissue has also revealed reduced BDNF protein levels in patients with bipolar disorder (Knable et al., 2004). In rodents, experimental interventions that cause manic-like (Frey et al., 2006; Fries et al., 2015; Jornada et al., 2010) and depressive-like behaviors (Smith et al., 1995; Tsankova et al., 2006; Ueyama et al., 1997) have also been shown to result in decreased BDNF mRNA and protein levels in the hippocampus. In contrast, lithium treatment is associated with increased BDNF protein levels.
in the serum of patients with bipolar disorder (Cunha et al., 2006; de Sousa et al., 2011; Tramontina et al., 2009). In rodent models, chronic lithium treatment has been shown to increase BDNF mRNA and protein expression in hippocampus, cortex, and amygdala as well as cortical neurons in culture (Fukumoto et al., 2001; Jornada et al., 2010; Yasuda et al., 2009). Lithium treatment has also been shown to increase TrkB activity in neuronal cultures suggesting an increase in BDNF-TrkB signaling (Hashimoto et al., 2002).

While previous work has demonstrated that BDNF is necessary for the antidepressant response of conventional antidepressants (Adachi et al., 2008; Ibarguen-Vargas et al., 2009; Monteggia et al., 2004, 2007), as well as the rapid antidepressant effects of ketamine (Autry et al., 2011; Lepack et al., 2014), it is currently unknown whether BDNF or the TrkB receptor are required for lithium’s antidepressant or antimanic effects. In this study, we establish the necessity of BDNF-TrkB signaling in the antimanic-like but not antidepressant-like response to lithium. We also identify a direct effect of lithium treatment on AMPAR trafficking, where AMPA receptor surface expression is decreased due to a sustained increase in dynamin mediated AMPAR endocytosis. This process is dependent on BDNF-TrkB function and results in synaptic downscaling where unitary postsynaptic responses are decreased in a manner proportional to their relative strengths. Collectively, our findings reveal a requirement for neurotrophic signaling in the behavioral and cellular effects of lithium. These data provide novel mechanistic insight into the action of lithium which may underlie its therapeutic effect for the treatment of bipolar disorder.
Results

Chronic lithium treatment increases BDNF expression

Previous studies have used mice to examine the impact of lithium treatment on molecular signaling. However, typically the lithium serum concentration is not determined in mice following lithium treatment leaving it unclear whether reported changes occur within the therapeutic range. We established a lithium protocol in which C57BL/6 mice were given 0.2% lithium chloride (LiCl) chow for four days, followed by 0.4% LiCl chow for the remainder of the treatment and testing period, which lasted a total of 11-17 days depending on the experiment (Fig 1A). This protocol resulted in a lithium serum concentration in treated mice that was within the therapeutic range of 0.5-2 mM (Amdisen, 1980), with an average concentration of 1 mM (Fig 1B). Control (CTL) mice were given the same chow without lithium.

Following 11 days of lithium treatment, mice were sacrificed and the hippocampus rapidly removed. To confirm our lithium protocol produced the expected molecular effects, we examined GSK3 inhibition (Klein and Melton, 1996; Stambolic et al., 1996), by measuring the phosphorylation of GSK3β at serine 9 with western blot analysis and found a significant increase relative to total GSK3β (Fig 1C). We next examined whether the lithium treatment regulated the expression of BDNF in the hippocampus. Using Q-PCR targeted to the coding exon of Bdnf, we found lithium treated mice had a significant increase in Bdnf mRNA expression (Fig 1D). We also found a significant increase in BDNF protein expression (Fig 1E) in lithium treated mice relative to CTL mice.

BDNF is required for the antimanic-like effect of lithium

Since lithium increases the expression of BDNF mRNA and protein levels, we investigated whether BDNF was necessary for lithium’s behavioral action. Inducible Bdnf KO mice, in which Bdnf is deleted ~70-80% in broad forebrain regions (Monteggia et al., 2004), were given lithium treated chow following our protocol (Fig 1A). To determine whether this lithium treatment produced the expected behavioral effects, we tested mice in the forced swim test (FST), a test with predictive value for antidepressant
responses (Porsolt et al., 1977). Littermate control (CTL) mice treated with lithium showed a significant reduction in immobility time that was suggestive of an antidepressant-like response compared to CTL mice that did not receive lithium (Fig 2A). In agreement with previous data we found that loss of Bdnf in the inducible Bdnf KO mice did not alter immobility in the FST compared to CTL mice (Monteggia et al., 2004). We also found that Bdnf KO mice administered lithium showed a significant reduction in immobility comparable to KO mice that did not receive lithium (Fig 2A) suggesting that BDNF is not necessary for the antidepressant-like effect of lithium in the FST.

To investigate whether BDNF was required for lithium’s antimanic-like effects, we used the amphetamine hyperlocomotor test in which lithium blunts the increased locomotor activity that occurs following acute amphetamine injection, a commonly used assay for the antimanic-like effects of lithium in mice (Flaisher-Grinberg and Einat, 2010; Gould et al., 2007). The amphetamine induced hyperlocomotor test was performed subsequent to the FST in the same cohorts of mice. Littermate CTL mice treated with acute amphetamine have the expected significant increase in the total number of horizontal beam breaks compared to vehicle treated mice (Fig 2B). CTL mice receiving lithium treatment showed a small non-significant increase in the total number of beam breaks compared to vehicle treated CTL mice, and were indistinguishable from chronic lithium treated mice receiving acute amphetamine, indicating that lithium treatment could prevent the hyperactivity induced by amphetamine (Fig 2B). In contrast, while inducible Bdnf KO mice receiving acute amphetamine showed a significant increase in the number of beam breaks compared to vehicle treated Bdnf KOs, and a slight increase with chronic lithium treatment, the chronic lithium treated Bdnf KO mice receiving acute amphetamine still had a significant increase in the number of beam breaks comparable to amphetamine treatment alone. These data demonstrate that lithium treatment does not block the hyperlocomotor effects of amphetamine in inducible Bdnf KO mice and thus suggests that BDNF is required for the antimanic-like effect of lithium.

We next assessed whether the loss of BDNF impacted lithium’s effect on synaptic efficacy from hippocampal slices. Inducible Bdnf KO and littermate control mice were given lithium treated chow or untreated chow (Fig 1A). The slope of the input/output (I/O) curve, which was plotted as the presynaptic
volley versus the fEPSC slope, was taken as a measure of synaptic efficacy associated with synaptic density or strength of individual synapse. We found that in CTL mice, chronic lithium treatment resulted in a significant reduction in the slope of the I/O curve in hippocampal slices in comparison to mice not treated with lithium (Fig 2C), indicating that chronic lithium treatment reduces hippocampal synaptic strength. Inducible Bdnf KO mice that did not receive lithium had a similar slope of the I/O curve compared to untreated littermate CTL mice (Fig 2C) showing that the loss of BDNF did not impact synaptic efficacy. We also found that the slope of the I/O curve in the hippocampal slices from the inducible Bdnf KO mice treated with lithium was also unchanged in comparison to the untreated CTL and Bdnf KO mice (Fig 2C), suggesting that BDNF expression is required for the lithium-mediated reduction of synaptic strength.

**BDNF and TrkB are required for lithium-mediated decreases in AMPAR mEPSC amplitudes**

Previous work has shown that lithium treatment produces a significant decrease in AMPAR miniature excitatory postsynaptic current (mEPSC) amplitudes in cultured neurons, which has been suggested to underlie the antimanic effects of lithium (Ankolekar and Sikdar, 2015; Du et al., 2008; Wei et al., 2010). We therefore incubated dissociated C57BL/6 hippocampal neurons with 1 mM LiCl or 1 mM NaCl, to control for changes in osmolarity, for 11-15 days and then recorded AMPAR mEPSCs (Fig. 3A). Lithium treatment resulted in a significant decrease in AMPAR mEPSC amplitudes in comparison to NaCl treated or untreated CTL neurons (Fig. 3B-D). To examine whether lithium’s effect on AMPAR mEPSC amplitudes was due to synaptic scaling, we plotted in rank order the amplitudes from each condition with a linear fit equation. We found that lithium treatment resulted in a 41% and 26% decrease in the slope compared to untreated and NaCl treatment, respectively (Fig. 3E). These data show lithium produces a downward scaling of all AMPAR mEPSC amplitudes and impacts post-synaptic homeostatic plasticity. Notably, lithium did not produce generalized effects on synaptic measures as there were no changes in mEPSC frequency compared to untreated or NaCl treated neurons (Fig. 3F). Since lithium’s effects on AMPAR mEPSC amplitudes were due to synaptic scaling, which can be influenced by
AMPAR trafficking, we examined the surface expression of the AMPAR subunit, GluA1. We performed surface biotinylation experiments and found lithium treatment results in a significant decrease in GluA1 surface expression relative to total GluA1 in comparison to untreated or NaCl treated neurons (Fig. 3G). Since our data demonstrated that BDNF was required for lithium’s antimanic-like effects in mice and lithium-mediated decrease in synaptic strength, we examined whether chronic lithium treatment’s effects on synaptic function, which may ultimately trigger the behavioral effects, were dependent on BDNF and its high affinity receptor TrkB. BDNF is a secreted protein that has been shown to influence synaptic upscaling and downscaling, depending on the brain region examined (Leslie et al., 2001; Reimers et al., 2014; Rutherford et al., 1998). We therefore examined whether lithium’s effects on AMPAR mEPSC amplitudes were dependent on BDNF. We cultured hippocampal neurons from Bdnf<sup>fl/fl</sup> mice and infected them with lentivirus expressing Cre recombinase (Cre) tagged with GFP to delete the gene of interest or GFP alone as a control. Previous studies from our laboratory have shown that this lentivirus construct expressing Cre tagged with GFP can efficiently knock out endogenous gene expression without triggering cell death (Akhtar et al., 2009; Nelson et al., 2006). As expected, GFP infected neurons treated with chronic lithium had a significant decrease in AMPAR mEPSC amplitudes in comparison to untreated or NaCl treated neurons (Fig. 4A-D). In BDNF deficient cultures, Bdnf<sup>fl/fl</sup> neurons infected with Cre, there was a slight but nonsignificant decrease in AMPAR mEPSC amplitudes compared to GFP infected neurons suggesting loss of BDNF does not impact this synaptic measure (Fig. 4A-D). In contrast to wild-type neurons, we found chronic lithium treatment of BDNF deficient cultures did not alter AMPAR mEPSC amplitudes (Fig 4D) suggesting a requirement for BDNF. We also examined mEPSC frequency from these six treatment groups and did not find a significant change with any condition (data not shown). Taken together, these data suggest that chronic lithium’s effect on AMPAR mEPSC amplitudes is dependent on BDNF.

To further evaluate whether BDNF signaling is required for lithium’s effects on AMPAR mediated synaptic transmission, we explored the requirement for the TrkB receptor. We cultured hippocampal neurons from Ntrk2<sup>fl/fl</sup> mice and infected them with either lentivirus expressing Cre or GFP.
Consistent with our previous results, GFP infected neurons treated with lithium had a significant decrease in AMPAR mEPSC amplitude compared to untreated or NaCl treated neurons (Fig. 5A-D). We found Ntrk2\textsuperscript{fl/fl} neurons infected with CreGFP, had indistinguishable AMPAR mEPSC amplitudes compared to GFP infected neurons demonstrating that loss of TrkB does not affect this synaptic measure (Fig 5D). In agreement with data from the Bdnf deficient neurons, we found lithium treatment of Ntrk2 deficient neurons did not affect AMPAR mEPSC amplitudes showing a requirement for TrkB in lithium’s effect on AMPAR mEPSC responses (Fig 5D). We measured mEPSC frequency in the six treatment groups and did not observe any significant differences demonstrating a specific effect of lithium on mEPSC properties (data not shown).

Dynamin-dependent endocytosis is required for lithium-mediated decrease in AMPAR mEPSC amplitudes

Our data so far shows that chronic lithium treatment of hippocampal neurons leads to a significant decrease in AMPAR mEPSC amplitudes that is dependent on BDNF-TrkB signaling. The decrease in AMPAR mEPSC amplitudes and the reduced GluA1 surface membrane expression suggests lithium is augmenting AMPAR endocytosis. Therefore, we examined whether inhibiting AMPAR endocytosis would rescue the synaptic phenotype observed with lithium treatment. AMPAR endocytosis is dependent on the GTPase dynamin (Lu et al., 2007), which is expressed by three related genes in mammals (Raimondi et al., 2011). Dynamin 1 and 3 (Dnm1 and Dnm3) are highly expressed in neurons and found in dendrites (Calabrese and Halpain, 2015; Noda et al., 1993). Previous work has shown that constitutive Dnm1\textsuperscript{-/-} / Dnm3\textsuperscript{-/-} double KO mice are not viable (Raimondi et al., 2011). Therefore, to examine the contribution of both dynamin1 and dynamin3 on lithium mediated synaptic effects, we crossed Dnm1\textsuperscript{fl/fl} mice with Dnm3\textsuperscript{-/-} mice as the constitutive deletion of Dnm3 does not impact synaptic function (Raimondi et al., 2011). We cultured Dnm1\textsuperscript{fl/fl} / Dnm3\textsuperscript{-/-} neurons and infected them with lentivirus expressing Cre to delete Dnm1 and thus generate the double KOs, or GFP as a control. The GFP infected neurons treated with lithium had a significant reduction in AMPAR mEPSC amplitudes.
compared to untreated neurons showing that the loss of Dnm3 does not impact the effect of lithium on synaptic function (Fig 6A-C). In contrast, deletion of both Dnm1 and Dnm3 occluded the effect of chronic lithium treatment on AMPAR mEPSC amplitudes in comparison to untreated cultures demonstrating that lithium is potentiating dynamin dependent endocytosis of AMPAR (Fig 6C).

To control for possible compensatory effects due to the loss of Dnm1 and Dnm3, in our next experiments we cultured hippocampal neurons from C57BL/6 mice and acutely inhibited dynamin activity in the postsynaptic neuron. We chronically treated neurons with lithium and then added the pan-dynamin inhibitor Dyngo (McCluskey et al., 2013), or the vehicle 1% DMSO, to the internal pipette solution prior to our recordings. Consistent with previous data, chronic lithium treatment resulted in a significant decrease in AMPAR mEPSC amplitudes in neurons recorded with vehicle in the pipette solution (Fig 6D-F). In contrast, the presence of Dyngo in the pipette solution rescued the decrease in AMPAR mEPSC amplitudes seen after lithium treatment (Fig 6F). Taken together, these experiments demonstrate that chronic lithium treatment enhances AMPAR endocytosis to alter synaptic function in a dynamin dependent manner and the loss of dynamin, specifically Dnm1 and Dnm3, can rescue the synaptic deficits.
In the current study, we report that lithium requires BDNF-TrkB signaling to mediate its antimanic as well as synaptic effects. Chronic lithium treatment in vivo results in a sustained increase in BDNF mRNA and protein expression. However, while BDNF is required for the antimanic effects of lithium it is not required for the antidepressant effects. We determined that chronic lithium treatment in vivo caused a significant decrease in I/O curves from hippocampal slices that were dependent on BDNF expression. We investigated the effect of chronic lithium on synaptic function and found a significant synaptic downscaling of AMPAR mEPSC amplitudes that was dependent on BDNF as well as its high affinity receptor, TrkB. The decrease in AMPAR mEPSC amplitudes was due to a decrease in postsynaptic surface expression of GluA1 driven by dynamin-dependent AMPAR endocytosis, which could be acutely countered by administration of a dynamin inhibitor. Collectively, these data demonstrate that lithium can target AMPA receptor endocytosis to alter synaptic function.

In these experiments we used lithium treated chow to administer the drug to mice to more closely mimic the oral administration used by patients with bipolar disorder. In initial experiments, we established a chronic lithium regimen that resulted in clinically relevant lithium levels in serum. In each experiment we confirmed that an animal had a serum lithium level of 0.5-3.0 mM/L to ensure that the molecular and behavioral studies were performed under conditions similar to long-term treatment for Bipolar Disorder. We show that chronic lithium treatment in rodents causes a sustained increase in BDNF mRNA and protein in the hippocampus. However, BDNF was not required for the antidepressant action of lithium. Previous studies have shown that BDNF is required for the antidepressant effects of traditional antidepressants (Adachi et al., 2008; Monteggia et al., 2004), as well as rapid antidepressant effects of ketamine (Autry et al., 2011). While the current data showing lithium can exert an antidepressant effect in inducible Bdnf KOs is unexpected, the finding could be due to several possibilities. First, these data may suggest that mood stabilizers mediate an antidepressant response in a manner distinct from conventional antidepressants that target the monoamine system and independent of BDNF. Second, previous work with traditional antidepressants has largely focused on changes in Bdnf
mRNA, with changes in BDNF protein not as fully explored leaving it unclear the time frame that conventional antidepressants increase BDNF protein (Duman and Monteggia, 2006). The rapid antidepressant action of ketamine requires BDNF and is protein translation dependent, with BDNF protein rapidly increased but then returning to baseline (Autry et al., 2011). In contrast, data from the current study shows that lithium treatment results in a sustained increase in Bdnf mRNA and protein expression. Taken together, these may data suggest acute manipulation of BDNF protein expression is involved in rapid antidepressant effects while a more chronic increase in BDNF expression is required for antimanic effects.

Lithium produces significant effects on synaptic transmission that may underlie its antimanic properties. Previous work has consistently shown that lithium application significantly decreases AMPAR mEPSC amplitudes in cultured neurons (Ankolekar and Sikdar, 2015; Du et al., 2004; Gray et al., 2003; Seelan et al., 2008; Wei et al., 2010). We replicated these data and showed chronic lithium treatment of hippocampal neurons results in a significant decrease in AMPA mEPSC amplitudes compared to control conditions. We also found that lithium treatment did not alter AMPA mEPSC frequency demonstrating specificity to the impact of the drug on synaptic transmission. Further analysis revealed that lithium produced a significant downward multiplicative synaptic scaling of all AMPAR-mEPSC amplitudes consistent with an impact on post-synaptic homeostatic plasticity. Previous in vivo and in vitro studies have shown that lithium decreases GluA1 and GluA2 surface expression in the hippocampus and in cultured cortical neurons (Du et al., 2003, 2008; Wei et al., 2010). In addition, we found that in vivo lithium treatment caused a significant decrease in I/O curves in hippocampal slices, which is reminiscent of the decreased AMPA/NMDA ratio previously seen in rats following chronic lithium treatment (Du et al., 2008). Lithium treatment has also been shown to decrease phosphorylation of Thr840 on GluA1, which is associated with decreased AMPAR signaling (Szabo et al., 2009). In the current study, we found that lithium treatment of hippocampal neurons elicits synaptic downscaling due to decreased GluA1 surface expression demonstrating a previously unknown effect of lithium on post-synaptic homeostatic plasticity.
The lithium triggered significant decrease on AMPAR mEPSC amplitudes and hippocampal I/O curves was occluded in neurons lacking Bdnf suggesting a requirement in lithium’s action. To confirm these data, we examined neurons with a deletion of Ntrk2 and found that lithium’s effect on AMPAR-mEPSC amplitudes was also occluded. While these data demonstrate that the effect of lithium on AMPA mEPSC amplitudes is dependent on BDNF and TrkB, the requirement for TrkB was more robust than BDNF per se. These findings may be due to low level expression of BDNF remaining after viral infection of Cre recombinase that acts on TrkB receptors or alternatively some minor effects of neurotrophin 3 (NT3) or neurotrophin 4 (NT4) activating the TrkB receptor to impact lithium’s effects on synaptic transmission. Regardless, these results demonstrate a rather unexpected requirement for BDNF-TrkB signaling in lithium mediated effects on synaptic scaling as increased BDNF expression is typically associated with increased AMPAR surface expression (Jakawich et al., 2010; Nakata and Nakamura, 2007; Nosyreva et al., 2013). However, there is precedent for BDNF to induce downscaling of AMPAR surface expression. Specifically, acute increases in BDNF have been shown to increase GluA1 and GluA2 surface expression, whereas chronic increases in BDNF decrease surface expression of GluA1 and GluA2 (Reimers et al., 2014). Collectively, these data suggest that chronic lithium treatment through a sustained increase in BDNF expression leads to synaptic downscaling.

The BDNF-TrkB dependence of lithium-mediated effects on mEPSC amplitudes was due to decreased surface expression of GluA1, suggesting the removal of AMPARs by endocytosis. In neuronal synapses, dynamin has been shown to be a key mediator of endocytosis. To determine whether lithium promotes AMPAR endocytosis by a dynamin-dependent mechanism, we utilized a genetic approach with deletion of Dnm1 and Dnm3 and reversed the lithium-mediated decrease in AMPAR mEPSC amplitudes. To further establish that lithium triggers AMPAR endocytosis, we treated individual cells acutely with the dynamin inhibitor, Dyngo and demonstrated that lithium’s impact on AMPAR endocytosis can be rapidly countered by dynamin inhibition. Previous work has shown that AMPAR internalization/endocytic membrane trafficking of the postsynaptic neuron can be regulated in a dynamin-dependent process to control strength (Lu et al., 2007). Taken together, our data show that lithium regulates dynamin-
dependent endocytosis and rapidly removes AMPAR from the postsynaptic membrane altering synaptic efficacy.

Altered glutamatergic signaling and hyperactivity have been implicated in the pathology of bipolar disorder. Mania in bipolar patients has been associated with elevated glutamate signaling (Lan et al., 2009; Öngür et al., 2008). In post-mortem brain tissue of individuals with bipolar disorder an increase in expression of the vesicular glutamate transporter (VGlut1) mRNA and glutamate have been observed (Eastwood and Harrison, 2010; Hashimoto et al., 2007). Human induced pluripotent stem cell (IPSC) derived neurons from patients with bipolar disorder were shown to have lower action potential thresholds, increased evoked and spontaneous action potentials, and larger action potential amplitudes suggesting they are hyperactive in comparison to neurons derived from healthy controls (Mertens et al., 2015). Conversely, lithium treatment has been shown to reverse the glutamatergic hyperactivity from IPSC derived neurons from patients with bipolar disorder (Mertens et al., 2015). In addition, recent work has suggested that lithium may alter neuronal activity by regulating G-protein gated inward rectifier K+ (GIRK) channels (Farhy Tselnicker et al., 2014), which may modulate homeostatic scaling of AMPAR responses. Although, we cannot exclude lithium-mediated regulation of neuronal activity as a component of our observations, a parsimonious interpretation of our results suggests that direct biochemical effects of lithium mediated signaling is the key driver for the AMPAR downscaling we observed. Our findings showing that lithium triggers dynamin-dependent endocytosis of AMPARs may be a way in which to counteract the increased glutamatergic signaling associated with mania. Further work will be necessary to pursue this hypothesis and explore the role of lithium on dynamin-dependent endocytosis as a potential mechanism in antimanic action.

Findings from the current study identify a critical role for BDNF in the antimanic and synaptic effects of lithium treatment. These results demonstrate that lithium specifically impacts excitatory neurotransmission by decreasing AMPAR-mEPSCs through dynamin-dependent endocytosis to reduce surface expression of AMPAR subunits. These data start to provide a framework to elucidate the
mechanisms underlying lithium’s effect on synaptic transmission which may offer insight into novel therapeutic targets for the treatment of bipolar disorder.

Materials & Methods

Animals

Male C57BL/6 mice aged 6-8 weeks were habituated to the animal facilities for at least 7 days prior to behavior testing. The mice were maintained on a 12-h light/dark cycle with ad libitum access to food and water, unless otherwise noted for lithium treatment groups. The Bdnf\textsuperscript{fl/fl} and Ntrk2\textsuperscript{fl/fl} mice were generated as previously described and maintained as homozygous crosses (Luikart et al., 2005; Rios et al., 2001). The inducible Bdnf knockout (KO) mice were generated as previously described (Monteggia et al., 2004). The Dnm1\textsuperscript{fl/fl} and the Dnm3\textsuperscript{-/-} null KO mice were generated as previously described (Ferguson et al., 2007; Raimondi et al., 2011). All behavioral testing was done with age and weight matched male mice that were balanced by genotype. In these experiments we utilized only male mice as previous work from our laboratory has shown that loss of BDNF can impact depression-related behaviors in a sex-dependent manner (Autry et al., 2009). All electrophysiology and biochemistry experiments utilized male and female mice. All experiments were performed and data analyzed by an experimenter blind to drug condition and genotype. Animal protocols were approved by the Institutional Care and Use Committee at UT Southwestern Medical Center.

Lithium Treatment in vivo

The lithium treatment consisted of mice given 0.2% lithium chloride (LiCl) chow (Harlan Teklad, East Millstone, NJ) for 4 days and then switched to 0.4% LiCl (Harlan Teklad) chow for the remainder of the study, which lasted from 11-17 days total. All mice received water as well as a bottle of 0.9% sodium chloride (NaCl) to control for ion imbalances known to occur with lithium administration. Control mice were kept on identical chow except it did not contain lithium.
Measurement of lithium in serum

Trunk blood was collected from all animals after the completion of the lithium treatment and behavioral testing. Whole blood was kept on ice until it was spun at 3,000 RPM at 4˚C for 10 min to separate red blood cells and serum. Lithium ion counts were made using a flame photometer (Jenway PFP7) and concentration was calculated following the construction of a standard curve. Mice with serum lithium concentrations below 0.5 mM and above 3 mM were excluded from behavioral and biochemical analyses.

Behavior

Forced Swim Test. The forced swim test (FST) was performed in accordance with published protocols (Gideons et al., 2014). In brief, mice were placed in a glass 4-L beaker with 3-L of 23 ± 2°C water for 6 min and test session were video-recorded. The last 5 min of each trial were scored by an observer blinded to drug condition and genotype to determine immobility time.

Locomotor Activity. Mice were habituated to the testing room for 1 hr and then given an intraperitoneal (i.p.) injection of amphetamine hydrochloride (Sigma, St. Louis, MO) at 2 mg/kg dissolved in saline or saline as a control. Mice were then immediately placed in standard home cages under red light and locomotor activity was measured for 2 hrs by photocell beams linked to computer acquisition software (San Diego Instruments, San Diego, CA). The total beam counts for the 2 hr period were collected as a measurement of amphetamine induced hyperactivity (Yates et al., 2007).

Hippocampal slice preparation and field potential electrophysiology

Mice chronically treated with lithium (11-17 days) were anesthetized with isoflurane before decapitation. The brain was removed and immersed for 2-3 min in ice-cold dissection buffer containing the following (in mM): 2.6 KCl, 1.25 NaH₂PO₄, 26 NaHCO₃, 0.5 CaCl₂, 5 MgCl₂, 212 sucrose and 10 glucose. The hippocampus was dissected out and cut with a vibratome into 400-μm-thick transverse sections in ice-
cold dissection buffer continuously supplied with 95% O\textsubscript{2} and 5% CO\textsubscript{2}. Area CA3 was surgically
removed from each slice immediately after sectioning. The sections recovered in oxygenated ACSF
containing the following (in mM): 124 NaCl, 5KCl, 1.25 NaH\textsubscript{2}PO\textsubscript{4}, 26 NaHCO\textsubscript{3}, 2 CaCl\textsubscript{2}, 2 MgCl\textsubscript{2} and
10 glucose, pH 7.4 (continuously equilibrated with 95% O\textsubscript{2} and 5% CO\textsubscript{2}) for 2-3 hr at 30°C. Hippocampal
slices were transferred to the recording chamber and perfused with ACSF at a rate of 2-3 ml/min at 30°C.
Field EPSPs (fEPSPs) were evoked by inserting a bipolar platinum-tungsten stimulating electrode
(Frederick Haer, Bowdoin, ME) into Schaffer collateral/commissural afferents. The extracellular
recording electrodes filled with ACSF (resistance, 1-2 M\textohm) were placed into the CA1 just beneath the
molecular layer. Baseline responses were collected every 30 s using an input stimulus intensity that
induced 30-40% of the maximum response. After a 20 min stable baseline, an ascending series of
stimulus input intensities (range, 5 to 200 μA) were applied and the input/output (I/O) curve was plotted
by the slope of fEPSP versus afferent volley amplitude. Data are presented as mean ± SEM and analyzed
using two-way ANOVA. Sidak’s multiple comparisons test were conducted after significant interaction
effects were found. A p value of <0.05 was required for statistical significance.

**Cell culture**

Dissociated hippocampal cultures were prepared as previously described (Kavalali et al., 1999; Reese and
Kavalali, 2015). Whole hippocampi were dissected from postnatal day 0-3 (P0-P3) mice. The
hippocampi were trypsinized (~10 mg/mL trypsin; Invitrogen), dissociated mechanically, and plated on
Matrigel (Corning Biosciences, Tewksbury, MA)-coated coverslips for electrophysiology or directly onto
tissue culture treated plates for protein collection for western blot analysis. At 1 d in vitro (DIV), 4 μM
cytosine arabinoside (ARAC; Sigma) was added. At 4 DIV, the ARAC concentration was decreased to 2
μM with a media change. Treatment with LiCl (1 mM) solution (Sigma) or NaCl (1 mM) solution
(Sigma) was initiated at 4 DIV and lasted for 11-17 days. The Bdnf\textsuperscript{fl/fl}, Ntrk2\textsuperscript{fl/fl}, and Dnm1\textsuperscript{fl/fl
cultures were infected with lentivirus expressing Cre recombinase (Cre) tagged with GFP or lentivirus expressing GFP alone as a control at 4 DIV. Lentivirus constructs and virus preparation from HEK293T/17 cells were prepared as previously described (Akhtar et al., 2009). HEK293T/17 cell line was purchased from ATCC (Cat. Number: CRL-11268). All electrophysiology experiments and protein collected for western blot analysis were done on 15-21 DIV cultures.

Patch-clamp Electrophysiology

Whole-cell patch clamp recordings were performed on hippocampal pyramidal neurons as previously described (Gideons et al., 2014). The external Tyrode’s solution contained (in mM): 150 NaCl, 4 KCl, 2 CaCl$_2$, 1.25 MgCl$_2$, 10 glucose, and 10 Hepes (pH 7.4) at ~300 mOsm. The pipette internal solution contained (in mM): 110 K-gluconate, 20 KCl, 10 NaCl, 10 Hepes, 0.6 EGTA, 4 Mg-ATP, 0.3 Na-GTP, and 10 lidocaine N-ethyl bromide (pH 7.3) at ~300 mOsm. Pipettes had a resistance between 3-7 M$\Omega$.

The junction potential between the internal and external solutions was ~12 mV and was subtracted from all recordings. AMPAR-mediated mEPSCs were recorded in the presence of 50 $\mu$M (2R)-aminoo-5-phosphonovaleric acid (AP5; Tocris, Bristol, UK), 1 $\mu$M tetrodotoxin (TTX; EMD Millipore, Billerica, MA), and 50 $\mu$M picrotoxin (PTX; Sigma). For the acute dynamin inhibitor studies, dynamin activity was inhibited in the postsynaptic neuron by adding 30 $\mu$M Dyngo-4A (Abcam, Cambridge, MA) to the internal pipette solution (McCluskey 2013). DMSO was added to the internal pipette solution as a control for these experiments. Data were acquired using a MultiClamp 700B amplifier and Clampex 10.0 software (Molecular Devices, Sunnyvale, CA). Recordings were sampled at 100 $\mu$s, filtered at 2 kHz with a gain of 5. No more than 3 recordings were obtained per coverslip. AMPAR-mEPSCs were analyzed from a 3-5 min recording using MiniAnalysis software by an experimenter blind to drug condition and genotype.

Quantitative RT-PCR
Briefly, fresh frozen hippocampi were dissected and total RNA was extracted using Trizol (Invitrogen) following the manufacturer’s instruction. Conditions for cDNA synthesis, amplification, and primer sequences were previously described (Adachi et al., 2008).

**Protein Quantification**

Anterior hippocampal slices (~1 mm thick, 2-3 per mouse) were dissected and flash-frozen following 11 days of lithium treatment or immediately following the last behavioral test depending on the experiment. Hippocampal tissue was lysed in a radio immunoprecipitation assay (RIPA) buffer containing: 50 mM Tris pH 7.4, 1% Igepal, 0.1% SDS, 0.5% Na deoxycholate, 4 mM EDTA, 150 mM NaCl, phosphatase inhibitors (10 mM Na pyrophosphate, 50 mM NaF, 2 mM Na orthovanadate), and protease inhibitors (Complete Mini tablets, Roche, Basel, Switzerland). Protein concentration was quantified with the Quick-Start Bradford assay (Bio-Rad, Hercules, CA). Approximately 30 µg of protein was electrophoresed on SDS-PAGE gels and then transferred to nitrocellulose membranes. The membranes were incubated with primary antibodies overnight at the following dilutions: BDNF (Abcam, Cat. Number: ab108319; RRID: AB_10862052), 1:1000, GAPDH (Cell Signaling, Cat. Number: 2118S; RRID: AB_561053) 1:50,000, phosphorylated GSK3β (Ser9, Cell Signaling, Cat. Number: 9323S) and total GSK3β (Cell Signaling, Cat. Number: 9315S) 1:30,000. Primary antibodies for phospho-GSK3β included 5% BSA. After washing, the membranes were incubated in anti-rabbit secondary antibodies: BDNF, 1:5000, GAPDH, 1:10,000, phospho-GSK3β and total GSK3β, 1:10,000. Protein bands were detected using ECL then exposed to film. Following development of phospho-GSK3β, membranes were stripped using Restore PLUS Western Blot Stripping Buffer (ThermoScientific, Waltham, MA), put in block, and then in primary antibody for total GSK3β. BDNF expression was normalized to GAPDH while a ratio of phospho- GSK3β intensity to total GSK3β was examined. The phospho-GSK3β and total GSK3β antibodies are known to recognize doublet bands (Cell Signaling).
Cell surface AMPAR expression measurement

Membrane biotinylation experiments were performed as previously described (Nosyreva et al., 2013). Dissociated hippocampal cultures from C57BL/6 mice were incubated in Tyrode’s solution containing 1 mg/ml sulfo-NHS-LC-biotin (Pierce/Thermofisher) for 20 min on ice. The biotin reactions were quenched by incubating the cultures in Tris-buffered saline (TBS) with 15 mM ammonium chloride for 5 min on ice, and then washed twice with TBS for 5 min on ice. Following the second TBS wash, the cultures were lysed in RIPA buffer (as described above) for 10 min on ice and spun at 12000 rpm for 5 min to remove non-solubilized material. Total protein concentration was quantified by Quik-Start Bradford assay (Bio-rad). 100 μg of protein from each sample was incubated with 100 μL of washed UltraLink NeutrAvidin (Pierce/Thermofisher) immobilized beads and rotated overnight at 4°C. Beads were washed with three times with RIPA buffer, followed by three washes with TBS at 4°C. Protein was eluted from the beads with SDS-PAGE sample buffer supplemented with β-mercaptaethanol (BME) for 10 min at 95°C. Eluted surface protein and 20 μg of total protein in SDS-PAGE-BME sample buffer were resolved by 10% SDS-PAGE gel, transferred to nitrocellulose, and probed with anti-GluA1 antibody (1:1000, Chemicon/EMD Millipore, Cat. Number: MAB2263) and anti-GAPDH antibody (1:50,000) overnight. Secondary anti-rabbit antibodies were at 1:2000 and 1:10,000 for GluA1 and GAPDH respectively. Surface GluA1 over total GluA1 ratio is reported.

Statistics

Data are reported as mean ± SEM. Statistical differences in the FST, locomotor tests, western blot, QPCR, mEPSC amplitude and frequency were assessed using unpaired two-tailed Student’s t test or one-way ANOVA when appropriate. Tukey and Bonferroni post hoc tests were used when appropriate. Differences in the cumulative probability histograms were assessed with Kolmogorov-Smirnov test. Statistical significance was defined at $P \leq .05$. Statistical outliers were identified with the Robust regression and Outlier removal (ROUT) method. All t-test, ANOVAs, associated post hoc tests, and
ROUT method statistical tests were performed with Prism 6 (GraphPad, La Jolla, California). The Kolmogorov-Smirnov test was performed using Past 3.02 (http://folk.uio.no/ohammer/past/).

Acknowledgements

We thank members of the Monteggia laboratory for helpful advice and discussions on the manuscript. We thank Dr. Rudolf Jaenisch for the Bdnf<sup>fl/fl</sup> mice and Dr. Luis Parada for the NtrkB<sup>fl/fl</sup> mice. This work was supported by National Institutes of Health Grants MH070727 (to L.M.M.) and MH066198 (to E.T.K.) as well as awards from the Brain & Behavior Research Foundation and the International Mental Health Research Organization (to L.M.M.).


Psychopharmacology (Berl.) 158, 100–106.


Figure legends

Figure 1. Lithium serum concentration within the therapeutic range increases BDNF expression in mice. (A) Timeline of chronic lithium chloride (LiCl) treatment and behavioral testing. (B) Example standard curve of lithium counts used to calculate lithium concentration in blood serum. (Right). Average lithium concentration in blood serum in control and treated mice (n= 9-12 per group). (C) Chronic lithium treatment in mice produces a significant decrease in immobility in the FST compared to the control group (Student’s unpaired t test *P<0.0001, n=10 mice per group). (D). Chronic lithium treatment caused a significant increase in Bdnf mRNA expression in the hippocampus (Student’s unpaired t test *P=0.04, n=8-9 mice per group). (E). Chronic lithium treatment caused a significant increase in BDNF protein expression in the hippocampus (Student’s unpaired t test *P=0.002, n=10 mice per group).

Figure 2. BDNF expression is required for the antimanic-like effect of lithium. (A) Chronic lithium treatment caused a significant decrease in the immobility time in the FST in littermate CTL and inducible Bdnf KO mice in comparison to vehicle chow treated mice (ANOVA F_{3,90}=18.1 *P<0.0001, Dunnett’s multiple comparisons Veh CTL vs LiCl CTL *P<0.0001, Veh Bdnf KO vs LiCl Bdnf KO *P<0.0001, n=19-28 mice per group). (B). Acute amphetamine injection caused a significant increase in locomotor activity in control and Bdnf KO mice in comparison to the saline injected mice. Lithium treatment resulted in a nonsignificant increase in locomotor activity of CTL and Bdnf KO mice compared to vehicle treated mice. Chronic lithium treatment blunted the increased locomotor activity following acute amphetamine injection in the CTL littermate mice, but not in the Bdnf KO mice (ANOVA F_{7,98}=12.75 P<0.0001, Tukey’s multiple comparisons CTL Veh-Sal vs CTL Veh-Amph *P<0.0001, CTL LiCl-Sal vs CTL LiCl-Amph P=0.97, CTL Veh-Sal vs CTL LiCl-Sal P=0.23, Bdnf KO Veh-Sal vs Bdnf KO Veh-Amph *P<0.0001, Bdnf KO LiCl-Sal vs Bdnf KO LiCl-Amph *P=0.01, Bdnf KO Veh-Sal vs Bdnf KO LiCl-Sal P= 0.44, n=11-15 mice per group). (C). Chronic lithium treatment resulted in a 20% reduction in the I/O curve in the CTL mice chronically treated with LiCl chow in comparison to Veh CTL mice, which is plotted as the slope of the fEPSP is plotted as a function of the presynaptic fiber volley. Linear
fit slopes were calculated for Veh CTL (5.53 ± 0.2) vs CTL LiCl (4.656 ± 0.03825). There were no
significant differences in the fEPSP slope between Veh Bdnf KO slices (5.85 ± 0.178) and LiCl treated
Bdnf KO (5.899 ± 0.1703). (Two-way ANOVA Interaction $F_{1,29}=3.24 \ P=0.08$, Row (Genotype) $F_{1,29}=5.09$
*P=0.032, Column (Diet) $F_{1,29}=12.61 \ *P=0.001$. Sidak’s multiple comparisons Veh CTL vs LiCl CTL
*P=0.029, Veh Bdnf KO vs LiCl Bdnf KO $P=0.999$, Veh CTL vs Veh Bdnf KO $P=0.739$, LiCl CTL vs
LiCl Bdnf KO *P=0.007 n=6-10 recordings per group).

**Figure 3. Chronic lithium treatment causes a significant decrease in synaptic scaling and surface GluA1 expression.** (A) Timeline for treatment of dissociated hippocampal neurons with LiCl and NaCl. (B) Example traces of AMPAR mEPSCs from CTL untreated (top), 1 mM NaCl treated (middle) and 1 mM LiCl treated (bottom) dissociated hippocampal neurons. (C) Chronic LiCl treatment of cultured hippocampal neurons caused a trend towards decreased AMPA mEPSC average amplitudes in comparison to CTL neurons. Chronic NaCl treatment did not cause a change in average AMPA mEPSC amplitude in comparison to CTL neurons (ANOVA $F_{2,39}=2.597 \ P=0.0873$, Bonferroni’s multiple comparisons CTL vs NaCl $P>0.999$, CTL vs LiCl $P=0.091$). (D) Cumulative probability histogram showing a significant leftward shift (decrease) in the amplitudes of AMPAR-mEPSCs from cells chronically treated with 1 mM LiCl in comparison to CTL untreated and 1mM NaCl treated neurons (Kolmogorov-Smirnov test: CTL vs 1 mM >LiCl *P=1.75x10^{-33}, D=0.234, 1mM NaCl vs 1mM LiCl *P=8.14x10^{-27}, D=0.167, n= 12-18 recordings per condition). (E) Rank order plot of CTL untreated AMPAR mEPSC amplitudes vs 1 mM LiCl AMPAR mEPSC amplitudes revealed a 41% decrease. Rank order plot of 1mM NaCl AMPAR mEPSC amplitudes vs 1 mM LiCl AMPAR mEPSC amplitudes showed a 26% decrease. (CTL vs LiCl line of best fit y=.59x, CTL vs NaCl line of best fit y=.85x, Difference between NaCl and LiCl .26, n= 12-18 recordings per condition). (F) AMPAR-mEPSC frequency is indistinguishable between CTL untreated, NaCl treated, and LiCl treated neurons (ANOVA $F_{4,57}=0.129 \ P=0.97$, n=12-18 recordings). (G) Surface biotinylation experiments revealed that chronic lithium treatment of hippocampal neurons results in a significant decrease in the surface/total GluA1 ratio
Figure 4. BDNF is required for the lithium-mediated decrease in AMPAR mEPSC amplitude. (A)
Example traces from GFP infected Bdnf<sup>fl/fl</sup> neurons with no treatment (CTL, top) or 11-17 day incubation with 1 mM NaCl (middle) or 1 mM LiCl (bottom). (B) Example traces from Cre infected Bdnf<sup>fl/fl</sup> neurons with no treatment (control, top) or 11-17 day incubation with 1 mM NaCl (middle) or 1 mM LiCl (bottom). (C) Cumulative probability histogram showing a significant leftward shift (decrease) in AMPAR mEPSC amplitudes between Bdnf<sup>fl/fl</sup>-GFP control untreated and Bdnf<sup>fl/fl</sup>-GFP LiCl conditions. There is also a significant leftward shift (decrease) between Bdnf<sup>fl/fl</sup>-GFP LiCl and Bdnf<sup>fl/fl</sup>-Cre LiCl conditions (Kolmogorov-Smirnov test: GFP Control vs GFP LiCl *P<0.0001, D=0.309, GFP LiCl vs Cre LiCl *P<0.0001, D=0.19, n=10-13 recordings per condition). (D) Lithium caused a significant decrease in AMPAR mEPSC amplitudes in Bdnf<sup>fl/fl</sup>-GFP neurons compared to control Bdnf<sup>fl/fl</sup>-GFP neurons. However, lithium did not impact AMPAR mEPSC amplitudes between Bdnf<sup>fl/fl</sup>-Cre neurons in comparison to untreated control Bdnf<sup>fl/fl</sup>-Cre neurons (ANOVA F<sub>5,59</sub>=5.694 *P=0.0002, Tukey’s multiple comparisons GFP Control vs GFP LiCl *P=0.003, Cre Control vs Cre LiCl P=0.197, n=10-13 recordings per condition).

Figure 5. Lithium-mediated decrease in AMPAR mEPSC amplitude is dependent on TrkB. (A)
Example traces from GFP infected Ntrk2<sup>fl/fl</sup> neurons, untreated Control (top), 1 mM NaCl treatment (middle), and 1 mM LiCl treatment (bottom). (B) Examples from Cre infected Ntrk2<sup>fl/fl</sup> neurons, untreated Control (top), 1 mM NaCl treatment (middle) and 1 mM LiCl treatment (bottom). (C) Cumulative probability histogram showing a significant leftward shift (decrease) in AMPAR-mEPSC amplitudes from Ntrk2<sup>fl/fl</sup>-GFP neurons treated with 1 mM LiCl. (Kolmogorov-Smirnov test: GFP control vs GFP LiCl *P<0.0001, D=0.181, GFP LiCl vs Cre LiCl *P<0.0001, D=0.153, n=9-17 recordings per condition). (D) Lithium caused a significant decrease in AMPAR-mEPSC amplitudes in Ntrk2<sup>fl/fl</sup>-GFP neurons.
neurons compared to untreated control $Ntrk2^{fl/fl}$-GFP neurons. However, lithium was unable to cause any significant changes in AMPAR-mEPSCs in $Ntrk2^{fl/fl}$-Cre neurons compared to untreated $Ntrk2^{fl/fl}$-Cre control (ANOVA $F_{5,76}=5.107^*P=0.0004$, Bonferonni multiple comparison test: GFP control vs GFP LiCl $*P=0.002$, Cre Control vs Cre LiCl $P>0.999$, $n=9-17$ recordings per condition).

Figure 6. Dynamin-dependent endocytosis is required for lithium-mediated decrease in AMPAR-mEPSC amplitudes

(A) Example traces from GFP infected $Dnm1^{fl/fl}/Dnm3^{-/-}$ neurons, control (top), chronic NaCl treatment (1 mM, middle) and chronic LiCl treatment (1 mM, bottom). (B) Example traces from Cre infected $Dnm1^{fl/fl}/Dnm3^{-/-}$ neurons, control (top), chronic NaCl treatment (1 mM, middle), and chronic LiCl treatment (1 mM, bottom). (C) Chronic lithium treatment caused a significant decrease in AMPAR mEPSC amplitude in $Dnm1^{fl/fl}/Dnm3^{-/-}$ neurons infected with lenti-GFP virus compared to untreated $Dnm1^{fl/fl}/Dnm3^{-/-}$ neurons. However, there was no significant difference in AMPAR-mEPSC amplitudes between untreated and lithium treated $Dnm1^{fl/fl}/Dnm3^{-/-}$ neurons infected with lenti-CreGFP virus (ANOVA $F_{5,68}=5.048^*P=0.0006$, Bonferonni multiple comparison test: GFP control vs GFP LiCl $*P=0.02$, Cre Control vs Cre LiCl $P=0.455$, $n=8-12$ recordings per condition). (D) Example traces from wildtype neurons recorded with DMSO-internal solution, control (top), chronic NaCl treatment (1mM, middle), and chronic LiCl treatment (1mM, bottom). (E) Example traces from wildtype neurons recorded with Dyngo-internal solution, control (top), chronic NaCl treatment (1mM, middle), and chronic LiCl treatment (1mM, bottom). (F). In comparison to control untreated neurons, chronic lithium treatment caused a significant decrease in AMPAR-mEPSC amplitudes. In contrast, lithium did not cause a significant change in AMPAR-mEPSC amplitudes in comparison to the untreated control when Dyngo is included in the internal pipette solution (ANOVA $F_{5,69}=6.985^*P<0.0001$, Bonferonni multiple comparison test: DMSO control vs DMSO LiCl $*P<0.0001$, Dyngo Control vs Dyngo LiCl $P>0.999$, $n=11-17$ recordings per condition).
**In vivo Lithium Treatment Timeline**

- **Day 1**
- **Day 5**
- **Days 12-15**

- 0.2% LiCl chow
- 0.4% LiCl chow

**Behavior**

**B**

- Li Counts vs. Li Concentration (mM)

**C**

- Western blot for p-GSK3β and Total-GSK3β

**D**

- Phospho/total GSK3β normalization

**E**

- Western blot for BDNF and GAPDH

- BDNF (normalized to GAPDH)
A

Cell Culture Lithium Treatment Timeline

Day 1
Culture

Day 4
Treat with LiCl or NaCl

Days 15-21
Record

B

CTL

1 mM NaCl

1 mM LiCl

20 pA
200 ms

C

AMPAR mEPSC Amplitude (pA)

CTL

1 mM NaCl

1 mM LiCl

D

Cumulative Probability (Percentage)

AMPAR mEPSC Amplitude (pA)

CTL

1 mM NaCl

1 mM LiCl

E

Chronic Treatment

AMPAR mEPSC Amplitude (pA)

CTL Treatment

AMPAR mEPSC Amplitude (pA)

F

AMPAR mEPSC Frequency (Hz)

CTL

1 mM NaCl

1 mM LiCl

G

Surface GluA1

Total GluA1

Surface/Total GluA1 ratio

CTL

NaCl

LiCl

26% decrease

*
A

Bdnf-fl/fl-GFP

Control

NaCl

LiCl

B

Bdnf-fl/fl-Cre

Control

NaCl

LiCl

C

Cumulative Probability (percentages)

AMPAR mEPSC Amplitude (pA)

GFP Control

GFP NaCl

GFP LiCl

Cre Control

Cre NaCl

Cre LiCl

D

AMPAR mEPSC Amplitude (pA)

GFP Control

GFP NaCl

GFP LiCl

Cre Control

Cre NaCl

Cre LiCl
A. *Dnm1fl/fl/DNM3−/−* control
   - NaCl
   - LiCl

B. *Dnm1fl/fl/DNM3−/−* Cre
   - NaCl
   - LiCl

C. *fIDyn1/Dyn3−/−* mEPSC Amplitude (pA)
   - GFP control
   - GFP NaCl
   - GFP LiCl
   - Cre control
   - Cre NaCl
   - Cre LiCl

D. *DMSO*
   - Control
   - NaCl
   - LiCl

E. *Dyngo*
   - Control
   - NaCl
   - LiCl

F. *Dyngo*
   - Control
   - NaCl
   - LiCl